Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Moxifloxacin ophthalmic solution - Alcon

Drug Profile

Moxifloxacin ophthalmic solution - Alcon

Alternative Names: AL-15469A; BAY-12-8039; BAY-X-8843; Kanavig; Moxafloxacin hydrochloride; Moxeza; Moxifloxacin hydrochloride ophthalmic solution - Alcon; Moxifloxacin hydrochloride otic solution - Alcon; Moxivig; Vegamox; Vigamox; Vigamoxi

Latest Information Update: 04 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Alcon
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Infectious conjunctivitis; Postoperative infections
  • Discontinued Otitis externa

Most Recent Events

  • 29 Sep 2023 Harrow Health is now called Harrow
  • 01 Aug 2023 Harrow completed new drug application (NDA) transfer for VIGAMOX®
  • 24 Jan 2023 Harrow health closes acquisition of US commercial rights of Moxifloxacin ophthalmic solution from Novartis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top